Antibody, reagent and kit for Kawasaki disease treatment effect evaluation and application of antibody, reagent and kit

A treatment effect, Kawasaki disease technology, applied in the direction of antibodies, anti-inflammatory agents, disease diagnosis, etc., to achieve the effect of reducing early misdiagnosis rate and reducing experience requirements

Inactive Publication Date: 2021-01-01
DAOZHI PRECISION MEDICINE TECH SHANGHAI CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, antibody markers for the diagnosis and e

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody, reagent and kit for Kawasaki disease treatment effect evaluation and application of antibody, reagent and kit
  • Antibody, reagent and kit for Kawasaki disease treatment effect evaluation and application of antibody, reagent and kit
  • Antibody, reagent and kit for Kawasaki disease treatment effect evaluation and application of antibody, reagent and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] This example provides the process of screening and obtaining 22 antibody sequences in this application.

[0034] (1) Carry out sample collection.

[0035] According to the diagnostic criteria for Kawasaki disease proposed by the American Heart Association, it includes fever of unknown etiology for ≥ 5 days, and five related symptoms (conjunctivitis, oral changes, limb changes, rash, and cervical lymphadenopathy). Complete KD was diagnosed if at least four symptoms were met, and incomplete KD otherwise. After being diagnosed with KD, the patient received high-dose IVIG (1g / kg per day, 1g per 1kg of body weight per day) combined with oral aspirin for two consecutive days.

[0036] From 4 patients diagnosed with Kawasaki disease (respectively numbered P1, P2, P3, P4), 2ml of peripheral venous blood was extracted from the patients on the 5th day of fever and 24 hours after IVIG was used for single-cell sequencing. Riddle.

[0037] From 3 healthy children (numbered H1, H2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antibody, a reagent and a kit for Kawasaki disease treatment effect evaluation and application of the antibody, the reagent and the kit. The antibody can be used as a markerfor Kawasaki disease treatment effect evaluation and can also be used for preparing a biomarker for high-risk judgment, a new thought is provided for clinical Kawasaki disease treatment effect evaluation, and the misdiagnosis rate of Kawasaki diseases can be reduced.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an antibody, reagent, kit and application thereof for evaluating the therapeutic effect of Kawasaki disease. Background technique [0002] Kawasaki disease (KD) was first reported by Japanese pediatrician Tomisaku Kawasaki in 1967. It is an acute, self-limited systemic vasculitis. The main clinical manifestations are fever, oral mucosal changes, rash, and cervical lymph nodes. Swelling, bulbar conjunctival hyperemia and extremity changes. Coronary artery lesion (CAL) caused by KD mainly includes coronary artery dilatation, coronary aneurysm, and later development of coronary artery stenosis. In severe cases, myocardial infarction, ischemic cardiomyopathy, and even sudden death may occur. [0003] my country has a large population base and a large number of children under the age of 5. It belongs to the Asian population with a high incidence of Kawasaki disease. In recent years, the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18G01N33/68A61K39/395A61P9/00A61P29/00
CPCC07K16/18G01N33/6893A61P9/00A61P29/00C07K2317/565A61K2039/505G01N2800/32
Inventor 刘佳王振谢利剑李光刘卫星宋思睿陈丽琴丁国徽黄敏
Owner DAOZHI PRECISION MEDICINE TECH SHANGHAI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap